Company: SUPN
Filing Date: 2025-11-06
Form Type: 10-Q
Source: 0001356576-25-000071
Chunk: 99

Company: SUPERNUS PHARMACEUTICALS, INC.
Filing Date: 2025-11-06
Form: 10-Q
Item: Part I, Item 1
Chunk 99
---
Supernus Pharmaceuticals, Inc.

Condensed Consolidated Balance Sheets

(in thousands, except share data)September 30,December 31,20252024(unaudited)AssetsCurrent assetsCash and cash equivalents$151,371 $69,331 Marketable securities129,789 384,281 Accounts receivable, net171,254 142,077 Inventories, net79,399 54,293 Prepaid expenses and other current assets62,078 36,088 Total current assets593,891 686,070 Restricted cash1,450 — Property and equipment, net10,627 11,545 Intangible assets, net623,481 521,912 Goodwill119,080 117,019 Deferred income tax assets, net8,793 — Other assets62,432 31,527 Total assets$1,419,754 $1,368,073 Liabilities and stockholders' equityCurrent liabilitiesAccounts payable and accrued liabilities$108,613 $76,352 Accrued product returns and rebates184,459 168,705 Contingent consideration, current portion11,235 47,340 Other current liabilities26,322 — Total current liabilities330,629 292,397 Contingent consideration, long-term213 — Operating lease liabilities, long-term31,422 27,382 Deferred income tax liabilities, net— 4,961 Other liabilities7,823 7,600 Total liabilities370,087 332,340 Commitments and contingencies (Note 17)Stockholders' equityCommon stock, $0.001 par value; 130,000,000 shares authorized; 57,119,153 and 55,743,095 shares issued and outstanding as of September 30, 2025 and December 31, 2024, respectively57 56 Additional paid-in capital527,700 479,440 Accumulated other comprehensive loss, net of tax(71)(189)Retained earnings521,981 556,426 Total stockholders' equity1,049,667 1,035,733 Total liabilities and stockholders' equity$1,419,754 $1,368,073 

See accompanying notes.

3

Table of Contents

Supernus Pharmaceuticals, Inc.

Condensed Consolidated Statements of Earnings (Loss)

(in thousands